In the latest trading session, 0.73 million Caribou Biosciences Inc. (NASDAQ:CRBU) shares changed hands as the company’s beta touched 1.97. With the company’s most recent per share price at $5.36 changed hands at -$0.5 or -8.56% at last look, the market valuation stands at $456.12M. CRBU’s current price is a discount, trading about -131.34% off its 52-week high of $12.40. The share price had its 52-week low at $3.96, which suggests the last value was 26.12% up since then. When we look at Caribou Biosciences Inc.’s average trading volume, we note the 10-day average is 2.79 million shares, with the 3-month average coming to 3.59 million.

Analysts gave the Caribou Biosciences Inc. (CRBU) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.60. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRBU as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Caribou Biosciences Inc.’s EPS for the current quarter is expected to be -$0.42.

Caribou Biosciences Inc. (NASDAQ:CRBU) trade information

Instantly CRBU was in red as seen in intraday trades today. With action -16.14%, the performance over the past five days has been red. The drop to weekly highs of 6.49 on Friday, 09/15/23 subtracted -8.56% to the stock’s daily price. The company’s shares are showing year-to-date downside of -14.67%, with the 5-day performance at -16.14% in the red. However, in the 30-day time frame, Caribou Biosciences Inc. (NASDAQ:CRBU) is -12.44% down. Looking at the short shares, we see there were 6.79 million shares sold at short interest cover period of 5.02 days.

The consensus price target for the stock as assigned by Wall Street analysts is $23.86, meaning bulls need an upside of 77.54% from its recent market value. According to analyst projections, CRBU’s forecast low is $19.00 with $30.00 as the target high. To hit the forecast high, the stock’s price needs a -459.7% plunge from its current level, while the stock would need to soar -254.48% for it to hit the projected low.

Caribou Biosciences Inc. (CRBU) estimates and forecasts

Data shows that the Caribou Biosciences Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 8.04% over the past 6 months, a 1.83% in annual growth rate that is considerably lower than the industry average of 11.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Caribou Biosciences Inc. will rise 4.50%, while the growth in revenue is estimated to hit 22.70% for the next quarter. Year-over-year growth is forecast to reach 35.20% up from the last financial year.

Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of $3.12 million. 5 analysts are of the opinion that Caribou Biosciences Inc.’s revenue for the quarter ending Dec 2023 will be $9.73 million. The company’s revenue for the corresponding quarters a year ago was $3.3 million and $3.69 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -5.50%. The estimates for the next quarter sales put growth at 163.50%.

The 2023 estimates are for Caribou Biosciences Inc. earnings to decrease by -47.20%, but the outlook for the next 5-year period is at -10.60% per year.

CRBU Dividends

Caribou Biosciences Inc. is expected to release its next quarterly earnings report in October.

Caribou Biosciences Inc. (NASDAQ:CRBU)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 13.73% of Caribou Biosciences Inc. shares while 59.40% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 68.86%. There are 59.40% institutions holding the Caribou Biosciences Inc. stock share, with Pfm Health Sciences, Lp the top institutional holder. As of Jun 29, 2023, the company held 6.31% of the shares, roughly 5.57 million CRBU shares worth $23.68 million.

Blackrock Inc. holds the second largest percentage of outstanding shares, with 5.40% or 4.76 million shares worth $20.25 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.48 million shares estimated at $6.29 million under it, the former controlled 1.68% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.50% of the shares, roughly 1.32 million shares worth around $9.51 million.